CTOs on the Move

Acucela

www.acucela.com

 
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.acucela.com
  • 1301 2nd Ave # 1900
    Seattle, WA USA 98101
  • Phone: 206.805.8300

Executives

Name Title Contact Details

Similar Companies

GI Pathology PLLC

GI Pathology PLLC is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Memphis, TN. To find more information about GI Pathology PLLC, please visit www.gipath.com

Renue Physical Therapy

Renue Physical Therapy was established in the Fall of 2011 with one clinic on Bay Road in Saginaw. Our goal from the start was to create a fully patient-focused practice model. We take pride in offering one-on-one treatment with the same therapy team throughout the course of therapy, providing a customized plan that is specific to your needs to help you achieve the best possible outcomes. Since our start in 2011, Renue has grown to more than 12 clinics serving the Great Lakes Bay Region and beyond, with locations in Auburn, Au Gres, Bay City, Bridgeport, Caro, Freeland, Midland, Saginaw and Shields.

Take Care Health Systems

Take Care Health Systems is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Conshohocken, PA. To find more information about Take Care Health Systems, please visit www.takecarehealth.com

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.

Gladden Longevity

Gladden Longevity is a comprehensive concierge medical program dedicated to health optimization and performance, with a focus on age reversal. They offer wellness and fitness services, neurocognitive testing, body composition analysis, cardiovascular p...